Biophagy announces the addition of Bhaskar Suda, PhD, to its team of consultants. Bhaskar will develop and run autophagy measuring assays and study proprietary compounds in neurodegenerative disorders.
Biophagy institutes a new division, CellWatch™, to develop its over-the-counter/direct-to-consumer products for the stimulation and measurement of autophagy in individuals.
Biophagy presents “Potential of Proprietary Molecules for Inducing Autophagy and Enhancing Antibiotic Treatment of Tuberculosis” at the Keystone Symposium, Tuberculosis: Immunity and Immune Evasion,” Santa Fe, NM
Biophagy presents “Autophagy: From Model Systems to Therapeutic Opportunities, 2/19/19, Keystone Symposium, Santa Fe, NM.
Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement.
Biophagy initiates a collaboration with Dr. Karin High, UNM, to study its proprietary compounds in chronic neuropathic pain, in vivo.
